- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV stock price live, this page displays NASDAQ LVTX stock exchange data. View the LVTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the LAVA Therapeutics NV real time stock price chart below.
What Is the LAVA Therapeutics NV Stock Price Today?
The LAVA Therapeutics NV stock price today is 1.530.
What Is the Stock Symbol for LAVA Therapeutics NV?
The stock symbol for LAVA Therapeutics NV is ""LVTX.""
What Stock Exchange Does LAVA Therapeutics NV Trade On?
LAVA Therapeutics NV is listed and trades on the NASDAQ stock exchange.
Is LAVA Therapeutics NV a Good Stock to Buy?
Determining whether LAVA Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LVTX quote. (ISIN: NL0015000AG6)
What Is the LAVA Therapeutics NV Stock Price Today?
The LAVA Therapeutics NV stock price today is 1.530.
What Is the Stock Symbol for LAVA Therapeutics NV?
The stock symbol for LAVA Therapeutics NV is ""LVTX.""
What Stock Exchange Does LAVA Therapeutics NV Trade On?
LAVA Therapeutics NV is listed and trades on the NASDAQ stock exchange.
Is LAVA Therapeutics NV a Good Stock to Buy?
Determining whether LAVA Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LVTX quote. (ISIN: NL0015000AG6)
NASDAQ
Currency in USD
1.530
+0.025(+1.66%)
Closed·
After Hours
1.540+0.010(+0.65%)
·
Fair Value
An estimate of a LAVA Therapeutics NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.450
1.560
52 wk Range
0.850
2.093
LVTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
1/2
Fair Value
An estimate of a LAVA Therapeutics NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4501.560
52 wk Range
0.8502.093
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LVTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a LAVA Therapeutics NV's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
1.381
Downside
-9.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
LAVA Therapeutics NV Company Profile
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
LAVA Therapeutics NV SWOT Analysis
Pipeline Pivot | Explore Lava Therapeutics' strategic shift following the discontinuation of LAVA-1207, and its focus on advancing LAVA-1266 for AML and MDS treatment |
Financial Fortitude | Delve into Lava's robust $86.8M cash position, providing runway into 2027 and flexibility for clinical trials and strategic opportunities |
Pharma Partnerships | Learn about Lava's collaborations with Pfizer and Johnson & Johnson, validating its technology and providing milestone payments |
Future Prospects | Analyst views vary, with JMP Securities adjusting from a $6 price target to Market Perform, reflecting uncertainty in Lava's evolving strategy |
Compare LVTX to Peers and Sector
Metrics to compare | LVTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLVTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −1.7x | −0.5x | |
PEG Ratio | −0.74 | −0.11 | 0.00 | |
Price/Book | 1.6x | 5.2x | 2.6x | |
Price / LTM Sales | 8.1x | 9.8x | 3.3x | |
Upside (Analyst Target) | −9.8% | 309.8% | 43.5% | |
Fair Value Upside | Unlock | 12.3% | 6.9% | Unlock |
Analyst Ratings
0 Buy
3 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1.381
(-9.76% Downside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-0.13 / -0.32
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does LAVA Therapeutics NV Trade On?
LAVA Therapeutics NV is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for LAVA Therapeutics NV?
The stock symbol for LAVA Therapeutics NV is "LVTX."
What Is the LAVA Therapeutics NV Market Cap?
As of today, LAVA Therapeutics NV market cap is 40.25M.
What Is LAVA Therapeutics NV's Earnings Per Share (TTM)?
The LAVA Therapeutics NV EPS (TTM) is -1.04.
When Is the Next LAVA Therapeutics NV Earnings Date?
LAVA Therapeutics NV will release its next earnings report on 25 Aug 2025.
From a Technical Analysis Perspective, Is LVTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has LAVA Therapeutics NV Stock Split?
LAVA Therapeutics NV has split 0 times.
How Many Employees Does LAVA Therapeutics NV Have?
LAVA Therapeutics NV has 34 employees.
What is the current trading status of LAVA Therapeutics NV (LVTX)?
As of 07 Aug 2025, LAVA Therapeutics NV (LVTX) is trading at a price of 1.53, with a previous close of 1.53. The stock has fluctuated within a day range of 1.45 to 1.56, while its 52-week range spans from 0.85 to 2.09.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.